Newly Diagnosed Glioblastoma Clinical Trial
Official title:
An Open-label Dose Escalation Study to Estimate MTD, Identify DLTs and Study Pharmacokinetics Following a Single Dose of Intracranially Administered Temozolomide-based SI-053 as an add-on to the Current Standard of Care, in Adult Patients With Newly Diagnosed Glioblastoma
SI-053 is a novel powder formulation containing temozolomide (TMZ), an alkylating chemotherapy agent, in an excipient which forms a viscous gel upon reconstitution in water. SI-053 will be used as an add-on to SoC for newly diagnosed GBM. SoC consists of maximal safe resection followed by radiation therapy (RT) with concomitant TMZ and adjuvant chemotherapy with TMZ. For MGMT promoter methylated GBM, lomustine and TMZ may be administered plus radiation therapy
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03899857 -
Pembrolizumab for Newly Diagnosed Glioblastoma
|
Phase 2 | |
Active, not recruiting |
NCT05163080 -
SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)
|
Phase 2 | |
Active, not recruiting |
NCT04474353 -
Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma
|
Phase 1 | |
Recruiting |
NCT05235737 -
The Assessment of Immune Response in Newly Diagnosed Glioblastoma Patients Treated With Pembrolizumab
|
Phase 4 | |
Recruiting |
NCT04840069 -
Radiotherapy Planning Using Fluciclovine PET in Patients With Newly Diagnosed Glioblastoma
|
Phase 2 | |
Active, not recruiting |
NCT03400917 -
Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma
|
Phase 2 | |
Completed |
NCT03619239 -
Dose-escalation Study to Evaluate the Safety and Tolerability of GX-I7 in Patients With Glioblastoma
|
Phase 1 | |
Completed |
NCT03345095 -
A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma
|
Phase 3 | |
Recruiting |
NCT04478279 -
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05864534 -
Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma
|
Phase 2 | |
Active, not recruiting |
NCT04600817 -
A Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT)
|
Phase 2 | |
Active, not recruiting |
NCT03782415 -
Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT04477200 -
Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma
|
Phase 1 | |
Withdrawn |
NCT04065087 -
Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients With Newly Diagnosed Glioblastoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT05380349 -
Personalized Cancer Stem Cell High-Throughput Drug Screening for Glioblastoma
|
Early Phase 1 |